AROMUC 5AC
Alternative Names: ARO-MUC5ACLatest Information Update: 28 Jul 2026
At a glance
- Originator Arrowhead Pharmaceuticals
- Class Antiasthmatics; Small interfering RNA
- Mechanism of Action Mucin 5AC expression inhibitors; RNA interference
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Asthma; Chronic obstructive pulmonary disease
- No development reported Obstructive airway disorders
Most Recent Events
- 28 Jul 2026 No recent reports of development identified for phase-I development in Obstructive airway disorders in Unknown (Inhalation)
- 23 Dec 2024 Arrowhead Pharmaceuticals terminates phase-I/IIa trial in Asthma and Chronic obstructive pulmonary disease (Treatment-experienced) in Australia, South Korea, New Zealand, Poland, Spain, Thailand and United Kingdom due to business reason (NCT05292950)
- 20 Jun 2023 Phase-I clinical trials in Obstructive airway disorders (Inhalation) (Arrowhead Pharma pipeline, June 2023)